Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 87, Issue 1, 2013, Pages 94-99

  Tendulkar, Rahul D ^a   Hunter, Grant K ^b   Reddy, Chandana A ^a   Stephans, Kevin L ^a   Ciezki, Jay P ^a   Abdel Wahab, May ^a   Stephenson, Andrew J ^c   Klein, Eric A ^c   Mahadevan, Arul ^d   Kupelian, Patrick A ^e  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b Intermountain Healthcare ^*  (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Seacoast Cancer Center New Hampshire   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIO-VASCULAR DISEASE; CUMULATIVE INCIDENCE; EXTERNAL BEAM RADIATION THERAPY; HIGH-RISK PROSTATE CANCERS; METHODS AND MATERIALS; MULTI VARIATE ANALYSIS; PROPORTIONAL HAZARDS; PROSTATE SPECIFIC ANTIGEN;

DOSIMETRY; RADIOTHERAPY; REGRESSION ANALYSIS;

DISEASES;

GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY MASS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CHARLSON COMORBIDITY INDEX; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE ESCALATION; SMOKING; TREATMENT DURATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME;

EID: 84881362647     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.05.044     Document Type: Article

References (17)

1. J.L. Mohler, A.J. Armstrong, and R.R. Bahnson Prostate cancer, version 3.2012: featured updates to the NCCN guidelines J Natl Compr Canc Netw 10 2012 1081 1087
2. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 2010 1117 1123
3. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 106
4. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
5. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290
6. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
7. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial JAMA 294 2005 1233 1239
8. P.C. Albertsen, J.A. Hanley, and G.H. Barrows Prostate cancer and the Will Rogers phenomenon J Natl Cancer Inst 97 2005 1248 1253
9. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
10. D.R. Cox Regression models and life-tables J Royal Stat Soc 34 1972 187 220
11. M.E. Charlson, P. Pompei, and K.L. Ales A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
12. J.P. Fine, and R.T. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
13. A. Jemal, R. Siegel, and J. Xu Cancer statistics, 2010 CA Cancer J Clin 61 2011 133 134
14. M. Roach 3rd, K. Bae, and J. Speight Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591
15. R.D. Tendulkar, C.A. Reddy, and K.L. Stephans Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy Int J Radiat Oncol Biol Phys 82 2012 1397 1404
16. S.L. Liauw, W.M. Stadler, and D. Correa Dose-escalated radiotherapy for high-risk prostate cancer: Outcomes in modern era with short-term androgen deprivation therapy Int J Radiat Oncol Biol Phys 77 2010 125 130
17. M.H. Stenmark, K. Blas, and S. Halverson Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease Int J Radiat Oncol Biol Phys 81 2011 e335 e344